PREVALENCE OF HPV DNA IN HIV INFECTED WOMEN WHO HAVE INITIATED HAART (A5029)

已开始 HAART 的 HIV 感染女性中 HPV DNA 的患病率 (A5029)

• 批准号: 7379061
• 负责人: Kenneth H. Fife
• 金额: $ 0.22万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379061
• 关键词: PREVALENCE; HPV; DNA; HIV; INFECTED

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HIV infection is a significant risk factor for HPV infection and the development of HPV-associated diseases. Today, treatment with HART has been demonstrated to result in significant increase in CD 4 cell counts and partial reconstitution of the immune system. A5029 is an observational, multicenter, prospective study designed to assess the conversion rate of HPV DNA among those HIV-infected subjects who have responded to HAART with suppressed HIV-1 RNA levels after 48 weeks. The study population includes antiretroviral-naive, HIV-infected, post-menarche females. Pap smears and other study data will be obtained prospectively from subjects at baseline, weeks 24,48 and every 48 weeks thereafter. The study will extend for 144 weeks after accrual of the last subject. A total of 160 subjects who are HIV-infected, antiretroviral naive, post-menarche females >13 years of age with 14 days of antiretroviral therapy at any time since HIV diagnosis will be enrolled. Subjects must be coenrolled in an approved Haart treatment trial, Phase II or higher, and will remain on A5029 even if they withdraw from the antiretroviral trial, as long as the antiretroviral trial HAART treatment was begun.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。HIV感染是HPV感染和HPV相关疾病发展的重要危险因素。今天，HART治疗已被证明导致CD 4细胞数量显著增加和免疫系统的部分重建。A5029是一项观察性、多中心、前瞻性研究，旨在评估48周后HIV-1 RNA水平被抑制的HAART应答的HIV感染者的HPV DNA转换率。研究人群包括抗逆转录病毒天真的、感染艾滋病毒的、初潮后的女性。巴氏涂片和其他研究数据将在基线、24周、48周和此后每48周从受试者中前瞻性地获得。这项研究将在最后一个受试者发生后延长144周。共有160名艾滋病毒感染者、未经月经初潮、13岁、自确诊以来任何时候接受过14天抗逆转录病毒治疗的女性将被纳入研究对象。受试者必须共同参加经批准的HAART治疗试验，即II期或更高阶段，并且即使他们退出抗逆转录病毒试验，只要抗逆转录病毒试验HAART治疗开始，他们也将继续服用A5029。